Adrenoleukodystrophy Clinical Trial
Official title:
Treatment of High Risk, Inherited Lysosomal And Peroxisomal Disorders by Reduced Intensity Hematopoietic Stem Cell Transplantation
Verified date | July 2019 |
Source | Masonic Cancer Center, University of Minnesota |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Hematopoietic stem cell transplantation has proven effective therapy for individuals with
adrenoleukodystrophy (ALD), metachromatic leukodystrophy (MLD) or globoid cell leukodystrophy
(GLD, or Krabbe disease). This protocol also considers other inherited metabolic diseases
such as, but not limited to, GM1 gangliosidosis, Tay Sachs disease, Sanfilippo syndrome or
Sandhoff disease, I-cell disease (mucolipidosis II).
For patients with advanced or rapidly progressive disease, the morbidity and mortality with
transplantation is unacceptably high. Unfortunately, there are no viable alternative
therapeutic options for these patients; if transplantation is not performed the patients are
sent home to die. Our group at Minnesota has developed a new protocol incorporating
transplantation using a reduced intensity conditioning regimen designed to decrease toxicity
associated with the transplant procedure. This regimen will make use of the drug clofarabine,
which has lympholytic and immune suppressive properties without the neurologic toxicity
observed in the related compound, fludarabine, commonly used for transplantation. In
addition, several agents providing anti-oxidant and anti-inflammatory properties will be used
to assist in the stabilization of the disease processes. This revised transplant protocol
will test the following: 1) the ability to achieve engraftment with the reduced intensity
protocol, 2) the mortality associated with transplant by day 100, 3) patient outcomes, based
on differential neurologic, neuropsychologic, imaging and biologic evaluations prior to
transplantation and at designated points after transplantation (day 100, 6 months, 1, 2 and 5
years). Additional biologic studies will include pharmacokinetics of clofarabine and
mycophenolate mofetil (MMF). In addition, for patients undergoing lumbar puncture studies,
cerebrospinal fluid (CSF) will be requested for determinations of biologic parameters.
Status | Completed |
Enrollment | 38 |
Est. completion date | September 2014 |
Est. primary completion date | September 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 70 Years |
Eligibility |
Inclusion Criteria: - Adrenoleukodystrophy: Patients from 0-55 years of age diagnosed with ALD as determined by very long chain fatty acid testing will be eligible for this protocol if they have evidence of cerebral or cerebellar disease based on MRI testing, AND they are determined high risk for any of the following reasons: 1. Age >18 years 2. MRI score >10 3. Evidence of aggressive disease that in the judgment of the Inherited Metabolic and Storage Disease group is sufficiently concerning to consider transplantation with a reduced intensity regimen instead of a standard full preparative regimen. - Metachromatic Leukodystrophy: Patients from 0-55 years of age diagnosed with MLD as determined by determinations of arylsulfatase A testing will be eligible for this protocol IF they are determined high risk for any of the following reasons: 1. Age >18 years 2. Symptomatic disease, as based on neurologic examination, or evidence of deterioration based on subsequent neuropsychologic evaluations. 3. Evidence of aggressive disease such as rapidly changing MRI determinations that in the judgment of the Inherited Metabolic and Storage Disease group is sufficiently concerning to consider transplantation with a reduced intensity regimen instead of a standard full preparative regimen. - Globoid Cell Leukodystrophy: Patients from 0-55 years of age diagnosed with GLD as determined by determinations of galactocerebrosidase testing will be eligible for this protocol IF they are determined high risk for any of the following reasons: 1. Age >18 years 2. Symptomatic disease, as based on neurologic examination, or evidence of deterioration based on subsequent neuropsychologic evaluations. 3. Evidence of aggressive disease such as rapidly changing MRI determinations that in the judgment of the Inherited Metabolic and Storage Disease group is sufficiently concerning to consider transplantation with a reduced intensity regimen instead of a standard full preparative regimen. - Patients with GM1 gangliosidosis, Tay Sachs disease, Sanfilippo syndrome, Wolman disease or Sandhoff disease or other inherited metabolic diseases including but not limited to I-cell disease (mucolipidosis II) who are determined to be sufficiently advanced or high risk based on the following reasons: 1. Symptomatic disease, as based on neurologic examination, or evidence of deterioration based on subsequent neuropsychologic evaluations. 2. Evidence of an expected poor outcome based on genetic testing or a prior family history of aggressive disease. 3. Other metabolic disorders, including but not limited to I-cell disease, that are deemed to be high-risk for a poor outcome with a standard transplant regimen due to anticipated toxicity based on experience gained at the University of Minnesota or other centers. Exclusion criteria: - Major organ dysfunction. - Advanced Disease Exclusion: Following evaluation, if a consensus of the members of the Inherited Metabolic and Storage Disease Program is that a patient is too advanced to benefit in a measurable and meaningful way from transplant, this will be communicated to the family, and transplant will not be offered. Measures to assist in those determinations may include: neurologic/neurocognitive functions such as activities of daily living, motor function, vision, hearing, interaction with environment, toileting, swallowing, or other standardized measures |
Country | Name | City | State |
---|---|---|---|
United States | Masonic Cancer Center, University of Minnesota | Minneapolis | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Masonic Cancer Center, University of Minnesota |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Patients With Donor Cell Engraftment | Donor Cell Engraftment is defined as the process of transplanted stem cells reproducing new cells. | Day 100 | |
Secondary | Number of Patients Whose Death Was Related to the Transplant | In the field of transplantation, toxicity is high and all deaths without previous relapse or progression are usually considered as related to transplantation. | Day 100 | |
Secondary | Concentrations of Mycophenylate Mofetil (MMF) | MMF levels are to be sent on day +3 to the main laboratory for determinations of MMF kinetics. Data was not collected on this outcome measure and is not available for reporting. |
Day 3 | |
Secondary | Number of Patients With Acute Graft Versus Host Disease (GVHD) | Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host. Acute GVHD can occur once the donor's cells have engrafted in the transplant recipient. The symptoms typically appear within weeks after transplant. | Day 100 | |
Secondary | Number of Patients With Chronic Graft Versus Host Disease (GVHD) | Graft-Versus-Host Disease is a severe complication created by infusion of donor cells into a foreign host. Chronic GVHD can appear at any time after allogeneic transplant or several years after transplant. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02254863 -
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
|
Phase 1 | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Completed |
NCT02961803 -
MD1003-AMN MD1003 in Adrenomyeloneuropathy
|
Phase 2/Phase 3 | |
Withdrawn |
NCT02948062 -
Early Diagnosis Of Childhood Cerebral ALD
|
||
Completed |
NCT02952482 -
Newborn Screening for Adrenoleukodystrophy
|
||
Recruiting |
NCT03789721 -
Adrenoleukodystrophy National Registry Study
|
||
Completed |
NCT04303416 -
Plasma Exchange With Albumin in AMN Patients
|
Phase 2/Phase 3 | |
Terminated |
NCT00545597 -
A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy
|
Phase 3 | |
Completed |
NCT03513328 -
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02699190 -
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
|
||
Recruiting |
NCT02559830 -
Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy
|
Phase 1/Phase 2 | |
Recruiting |
NCT00278044 -
Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children
|
N/A | |
Completed |
NCT00176904 -
Stem Cell Transplant for Inborn Errors of Metabolism
|
Phase 2/Phase 3 | |
Completed |
NCT00007020 -
Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
|
Phase 3 | |
Active, not recruiting |
NCT03231878 -
A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.
|
Phase 2/Phase 3 | |
Recruiting |
NCT03047369 -
The Myelin Disorders Biorepository Project
|
||
Recruiting |
NCT04925349 -
Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy and Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
|
||
Active, not recruiting |
NCT00005900 -
Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT00004450 -
Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy
|
N/A | |
Recruiting |
NCT04090268 -
Precision Exercise in Children With Malignant Hemopathies
|
N/A |